PROCEED evaluated the safety and survival profile of PROVENGE. Among patients in the lowest baseline prostate-specific antigen (PSA) quartile (≤5.27 ng/mL), nearly half (44.1%) of the men in the registry received no additional cancer treatments for at least 1 year.

Feb 17, 2020 · Provenge (sipuleucel-T), a personalized cancer vaccine, extended survival by nearly 15 months over oral hormone therapy, according to a retrospective study of more than 6,000 men, researchers reported at the American Society of Clinical Oncology Genitourinary Cancers Symposium last week in San Francisco.

Oct 20, 2020 · Provenge (sipuleucel-T), by Dendreon Pharmaceuticals, is superior to Zytiga (abiraterone acetate) or Xtandi (enzalutamide) at prolonging the lives of men with metastatic castration-resistant prostate cancer (mCRPC) when added at any point in a treatment regimen, according to a real-life study in the U.S.

Sep 9, 2019 · Treatment with the immunotherapy Provenge (sipuleucel-T) in a real-world setting is showing similar safety and efficacy in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) as in clinical trials, a study shows.

What is PROVENGE and how does it work? PROVENGE (sipuleucel-T) is an autologous cellular immunotherapy designed to stimulate a patient’s own immune system against cancer. PROVENGE is manufactured...

PROVENGE Treatment. Targeted immune response: PROVENGE starts with your patient’s own immune system and activates his antigen-presenting cells (APCs) to help the immune system target and attack prostate cancer cells. 1,2. See the Science behind PROVENGE

At 36 months, a survival benefit of 4.1 months was noted with sipuleucel-T; median survival was 25.8 months with sipuleucel-T and 21.7 months with placebo. Overall survival was significantly prolonged for sipuleucel-T patients ( P = 0.032; HR = 0.775) at the time of cutoff.

Jun 29, 2018 · Compared to placebo (which is superior to no treatment) Provenge has shown itself to extend survival. “Provenge delivered a statistically overall survival advantage - nearly 38% more patients were still alive 3 years post treatment in the Provenge group compared to the control.” (provengehcp.com)

PROVENGE is a personalized immunotherapy that activates your body’s immune system to fight advanced prostate cancer. Studies have shown that certain men who receive PROVENGE live longer. PROVENGE is recommended by nationally recognized medical organizations. PROVENGE has been proven to extend life for certain men with mCRPC.

Mar 8, 2009 · Provenge® immunotherapy prolongs survival in advanced prostate cancer - very effective in African Americans. Among all men with metastatic, hormone-refractory prostate cancer, the immunotherapy agent Provenge® (sipuleucel-T) …